Deramiocel

Duchenne muscular dystrophy causes progressive muscle degeneration. A systematic review estimated global birth prevalence at 19.8 per 100,000 live male births. In studies of people receiving ventilatory support, reported median life expectancy ranged from 21.0 to 39.6 years. A United States household study reported mean costs over five years of $78,303 for home and vehicle expenses and $14,071 for medical equipment. In a separate caregiver study, 383 of 770 caregivers reported moderate or extreme anxiety or depression.

HOPE-3 randomized 106 participants. The reported baseline population included 90 non-ambulatory participants (84.9%). The publication reported a 4.55-percentage-point between-group difference in mean percentage change in total PUL2.0 score at 12 months, favouring deramiocel (95% CI 0.47 to 8.63; p=0.029). The key secondary LVEF endpoint did not reach statistical significance (p=0.0935). FDA concluded that the study did not meet its prespecified primary and secondary efficacy endpoints and identified additional statistical changes without an updated SAP. These assessments should not be treated as equivalent analyses. In the FDA safety presentation, headache occurred in 32 of 53 deramiocel recipients (60.4%) and 2 of 52 placebo recipients (3.8%); hypersensitivity reactions occurred in 22 of 53 (41.5%) and 8 of 52 (15.4%), respectively.

Deramiocel remains an investigational treatment. Following a complete response letter and resubmission, the sponsor reported a PDUFA target action date of November 22, 2026 and a refined proposed indication focused on upper limb function. The advisory committee voted 3 in favour and 9 against effectiveness for DMD-associated cardiomyopathy, with no abstentions; the vote was non-binding. The published upper-limb analysis, the nonsignificant key cardiac endpoint, and FDA’s assessment of the prespecified analyses leave uncertainty about the efficacy conclusions and the eventual indication. A target action date does not establish approval.